The answer to whether you should use PAT-INFORMED to find drug patent loss-of-exclusivity dates depends entirely on who you are, what country’s market you’re analyzing, and what decision you’re trying to make. For a procurement officer in a low- or middle-income country trying to understand whether a specific medicine is off-patent in their jurisdiction, PAT-INFORMED is a reasonable starting point. For a generic pharmaceutical company assessing U.S. market entry strategy, it is nearly useless. For an investor modeling revenue cliffs in developed markets, it is structurally inadequate. Understanding those distinctions requires knowing how the database was built, who built it, and — critically — who funded its construction.
PAT-INFORMED launched in September 2018 as a joint initiative between the World Intellectual Property Organization (WIPO) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), with 20 originator pharmaceutical companies voluntarily providing patent data for their approved products. That sentence contains the single most important fact about the database: the patent data comes directly from the companies that hold the patents. There is no independent verification mechanism. There is no third-party audit. There is no obligation for completeness.
This article examines PAT-INFORMED systematically — its architecture, its genuine strengths, its structural limitations, and the situations in which it should be supplemented or replaced by the FDA Orange Book, MedsPaL, the USPTO Patent Center, or commercial databases like DrugPatentWatch. The goal is to give you a precise map of when to trust the tool and when to distrust it.
What Is PAT-INFORMED and Who Built It?
PAT-INFORMED — an acronym for Patent Information Initiative for Medicines — is a free, open-access database hosted by WIPO that links approved pharmaceutical products to the patents that cover them. Users search by International Nonproprietary Name (INN), the WHO-standardized generic name for an active pharmaceutical ingredient, and receive a list of granted patents associated with that medicine, organized by country.
The database currently contains information on over 18,900 individual patents across more than 636 patent families, covering 169 INNs across six therapeutic areas: HIV/AIDS, cardiovascular diseases, diabetes, hepatitis C, oncology, and respiratory conditions. It also covers products on the WHO Model List of Essential Medicines outside those six areas. The initiative is being expanded to additional therapeutic areas, though the timeline for that expansion has shifted repeatedly since the 2018 launch.
The 20 founding pharmaceutical companies include AbbVie, Astellas Pharma, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, and others. Each company voluntarily submits patent data for its products in the covered therapeutic areas. WIPO hosts the database and provides links to its own PATENTSCOPE global patent database where possible, but it does not independently verify the accuracy of what the companies submit.
How PAT-INFORMED Differs from Other Patent Databases
The key structural distinction is the data source. The FDA Orange Book links approved U.S. drug products to their listed patents using data that drug sponsors are legally required to submit under the Hatch-Waxman Act, subject to false-listing liability and FDA ministerial review. The USPTO Patent Center is a primary source showing every patent’s actual legal status, including maintenance fee payments and prosecution history. MedsPaL, operated by the Medicines Patent Pool, draws its data primarily from national and regional patent offices and public licensing agreements.
PAT-INFORMED, by contrast, relies exclusively on voluntary disclosure by the patent-holding companies themselves. The official WIPO FAQs acknowledge this directly: the data is “provided directly by the biopharmaceutical companies.” A procurement agency using PAT-INFORMED is, in effect, asking the patent holder to tell them how long the patent lasts. That is not categorically wrong as a source of information — companies have reputational and legal incentives to be accurate — but it creates a specific, predictable type of bias that any serious analyst needs to account for.
The Voluntary Participation Problem: Who Is Missing from the Database?
PAT-INFORMED covers only the 20 companies that chose to participate. Hundreds of pharmaceutical companies hold patents on medicines in the covered therapeutic areas and are not represented in the database at all. A drug that falls within PAT-INFORMED’s stated therapeutic scope may have no entry if its patent holder is not a participant. Equally important, a participating company may have patents in a country that it did not choose to include in its submission.
When a medicine is absent from PAT-INFORMED, the database provides no indication of whether the absence means no patents exist or simply that the company chose not to disclose them. The official FAQs state that the database “will also disclose information about the absence of relevant patents in a given country, where appropriate,” but that qualification — “where appropriate” — is defined by the company, not by an independent standard. This is not a minor footnote. It is the central structural problem with using PAT-INFORMED as a tool for establishing loss-of-exclusivity dates.
The Conflict-of-Interest Problem: Reading the MSF Technical Brief
In December 2019, Médecins Sans Frontières (MSF) and other civil society organizations submitted a technical brief to the WIPO Standing Committee on Patents, explicitly contesting the accuracy and independence of PAT-INFORMED. The document is specific, detailed, and damaging to the database’s credibility for any professional trying to use it as a tool for competitive intelligence or procurement decision-making.
The brief’s central charge is that PAT-INFORMED’s data is “selective, incomplete and oftentimes erroneous” and that the omissions appear to favor the commercial interests of the patent-holding companies that submit the data. The document provides a concrete example using daclatasvir, Bristol-Myers Squibb’s hepatitis C treatment.
The Daclatasvir Case: How Selective Disclosure Works in Practice
BMS had widely withdrawn its primary compound patent on daclatasvir in numerous low- and middle-income countries. The Medicines Patent Pool’s MedsPaL database recorded those withdrawals, identifying that countries including Armenia, Belarus, Kyrgyzstan, Kazakhstan, Moldova, and Tajikistan had no blocking patents — meaning procurement agencies in those countries were free to source generic versions. The PAT-INFORMED database, by contrast, showed only the countries where BMS had a granted and maintained patent. The withdrawals were absent.
The brief also identified cases in which PAT-INFORMED showed a patent as granted in a country — specifically Malaysia, Indonesia, and Uganda in the daclatasvir examples — when in fact no blocking patent existed. An Indonesian procurement agency consulting PAT-INFORMED would conclude a patent had been granted and might choose not to procure the cheaper generic version, even though procurement of the generic was legally permissible. At the time of the analysis, generic daclatasvir was available for $7-13 per bottle while BMS’s originator version was priced at up to $11,800 per bottle in certain markets. The stakes of that discrepancy are not abstract.
No Licensing Information: The Missing Layer That Changes Every Procurement Decision
PAT-INFORMED contains no information about voluntary licenses, compulsory licenses, or government-use licenses. For any medicine covered by a Medicines Patent Pool voluntary license, the existence of that license is frequently more relevant to procurement than the patent status itself — because a valid voluntary license may allow generic procurement in a territory even if blocking patents remain in force. PAT-INFORMED does not show this. MedsPaL does.
This omission is not incidental. Voluntary licenses are commercial agreements that determine which generic manufacturers can legally supply which markets. A procurement officer unaware of an existing voluntary license may conclude that a patent blocks generic procurement when the license has already cleared that path. PAT-INFORMED’s architecture structurally excludes this information.
“Pat-INFORMED is an important contribution to greater patent transparency on pharmaceuticals. It complements MedsPaL, which sources its data primarily from public records.” — Charles Gore, Executive Director, Medicines Patent Pool [1]
That framing — “complements” — is diplomatic. The two databases use fundamentally different data sourcing philosophies, and for questions about access in low- and middle-income countries, MedsPaL’s approach of drawing from public records and licensing agreements produces more reliable results than PAT-INFORMED’s self-reported model.
The Inquiry Mechanism: Why Direct Company Contact Is Not a Neutral Feature
PAT-INFORMED provides a facility for procurement agencies to make follow-up inquiries directly to the patent-holding companies. WIPO and IFPMA present this as a positive feature — a way to get additional clarity. The MSF brief reads it differently: as a mechanism that compels procurement agencies into direct commercial contact with the patent holder, where the patent holder controls the information and where the exchange is private, not publicly logged.
An independent procurement agency that starts with incomplete or misleading patent data and then contacts the patent holder for clarification is not getting independent information. It is beginning a negotiation with the counterparty that has the most to gain from its confusion. Whether or not individual company representatives act in good faith, the structural incentive is clear. This is not a flaw in PAT-INFORMED’s implementation; it is a consequence of its design.
What PAT-INFORMED Actually Does Well
The criticisms above are real and documented. They do not mean the database has no value. PAT-INFORMED performs a specific function reasonably well: giving procurement officers in countries without a local equivalent of the FDA Orange Book a starting point for understanding whether a medicine has patent coverage in their jurisdiction.
Before PAT-INFORMED launched in 2018, there was no free, searchable global database that directly linked approved medicines to their patents by INN. The FDA Orange Book covers only U.S.-approved products. National patent registers, where they exist, require jurisdiction-by-jurisdiction searches and do not link patents to specific commercial products. PATENTSCOPE provides access to international patent applications but requires significant technical skill to translate a patent filing into a product-level patent status determination.
Why Procurement Agencies in LMICs Benefit Most from PAT-INFORMED
A procurement manager at a public health ministry in sub-Saharan Africa, trying to determine whether a specific antiretroviral is under patent in their country before publishing a tender, faces a genuine information gap. National patent offices in many countries have limited resources and inconsistent online search capabilities. Hiring an IP law firm to conduct a full freedom-to-operate analysis for every medicine on a formulary is cost-prohibitive. PAT-INFORMED provides a free, INN-searchable starting point that requires no technical IP expertise to use.
Wesley Kreft of i+solutions, a Netherlands-based NGO specializing in medicines procurement for developing countries, stated that PAT-INFORMED had the potential to reduce procurement cycle times by 30% by shortcutting the initial patent status research phase. That is a meaningful efficiency gain in a context where procurement delays directly affect patient access. The database’s usefulness is real; it is the database’s limitations that are equally real and less frequently communicated.
The INN Search Interface: Simpler Than Any Alternative
PAT-INFORMED’s interface is genuinely easy to use. A user types a medicine’s INN — ‘tenofovir’, ‘imatinib’, ‘sofosbuvir’ — and receives a list of patents organized by country, with patent numbers linked to PATENTSCOPE where available. For a procurement professional unfamiliar with patent databases, this is substantially more accessible than searching the USPTO by assignee name or attempting to identify patent families across PATENTSCOPE without formal training.
The INN structure is also important for cross-border procurement coordination. Because INNs are globally standardized, a procurement network operating across multiple countries can use a single PAT-INFORMED search as a reference point before commissioning more detailed jurisdiction-specific analysis. The issue is that this reference point carries the structural caveats described above and should not be used as a terminal determination of patent status.
PAT-INFORMED vs. FDA Orange Book: When U.S. LOE Analysis Requires a Different Tool
For any analysis focused on U.S. drug loss-of-exclusivity dates, the FDA Orange Book is the mandatory starting point. PAT-INFORMED is structurally inadequate for U.S. LOE analysis because it does not include regulatory exclusivities, does not reflect the Paragraph IV certification and litigation process, does not account for Patent Term Adjustment or Patent Term Extension modifications, and does not cover products outside its therapeutic area scope.
What the FDA Orange Book Provides That PAT-INFORMED Cannot
The Orange Book, formally titled “Approved Drug Products with Therapeutic Equivalence Evaluations,” is published by the FDA and updated monthly. It serves two functions simultaneously: it lists the patents that drug sponsors have submitted for Orange Book inclusion, and it records the regulatory exclusivities the FDA has granted. Understanding U.S. LOE dates requires both, because the operative protection is whichever expires last — the final relevant patent or the final regulatory exclusivity.
Regulatory exclusivities operate independently of patents. A New Chemical Entity (NCE) exclusivity grants five years of market protection from the date of NDA approval during which the FDA will not accept competing ANDA or 505(b)(2) applications. An Orphan Drug Exclusivity (ODE) grants seven years of protection for the orphan indication. A three-year clinical investigation exclusivity attaches when a new clinical study supports a supplemental approval. Pediatric exclusivity under the Best Pharmaceuticals for Children Act adds six months to all unexpired patents and all unexpired regulatory exclusivities simultaneously — not just one patent, but the entire protection stack.
PAT-INFORMED has no equivalent mechanism. It lists patents. It does not list FDA-granted regulatory exclusivities. For any drug still within an NCE, Orphan, or pediatric exclusivity period, a patent-only analysis produces a systematically early LOE estimate, because the regulatory exclusivity may extend competition barriers beyond the last patent’s expiration.
The Orange Book’s Own Limitations: Why Patent Listing Is Not the Same as LOE Date
The Orange Book has well-documented limitations that compound the problem. The FDA does not verify the validity of patents that companies list. It performs a ministerial review — checking that the patent claims cover the approved drug and that the patent number is valid — but does not assess whether the claims are broad or narrow, strong or weak, likely to survive a Paragraph IV challenge. Brand manufacturers have strong incentives to list every patent that could plausibly cover their product, which produces Orange Books with patents that courts later invalidate.
The listed patent expiration dates in the Orange Book are the statutory 20-year-from-filing dates adjusted for any Patent Term Adjustment the USPTO has granted, but the Orange Book does not consistently reflect Patent Term Extensions, which require a separate search of the USPTO Patent Term Extension database. It also does not reflect the six-month pediatric exclusivity extension, which is a regulatory exclusivity that must be checked separately from the patent listing.
Patent Term Adjustment (PTA) vs. Patent Term Extension (PTE): Two Different Mechanisms
Patent Term Adjustment compensates patent holders for delays caused by the USPTO during prosecution. PTA accumulates day-by-day during examination and is calculated at the time the patent issues, adding days or months to the 20-year statutory term. A compound patent filed in 2000 that experienced significant USPTO examination delays might issue with 18 months of PTA, producing an effective expiration in mid-2022 rather than the statutory expiration in 2020.
Patent Term Extension under 35 U.S.C. § 156 compensates patent holders for time spent in FDA regulatory review. It applies to only one patent per drug product, adds up to five years to the patent term, and cannot result in more than 14 years of patent protection after the drug’s FDA approval. PTE is applied to the compound patent in most cases, making that patent — not a formulation or method-of-use patent — the one most likely to carry extended exclusivity.
Neither PTA nor PTE is consistently reflected in PAT-INFORMED. The database lists patent numbers and expiration dates as provided by the companies, but the methodology for how those dates are calculated is opaque. For precision LOE work in the U.S. market, the analyst must independently verify PTA from the USPTO Patent Center and check whether a PTE has been granted and applied.
Why the Paragraph IV Litigation Timeline Matters More Than Patent Expiry for U.S. Market Entry
For the U.S. market specifically, the practical date of generic entry frequently has nothing to do with the nominal patent expiration date. Generic manufacturers routinely challenge Orange Book-listed patents through Paragraph IV certifications, which assert that the listed patent is invalid, unenforceable, or not infringed by the proposed generic product. If the brand-name sponsor files a patent infringement suit within 45 days of receiving the Paragraph IV notice, FDA approval of the ANDA is automatically stayed for 30 months or until a court ruling, whichever comes first.
This litigation process means that the actual market entry date for a generic can arrive years before the patent expiration date (if the challenger wins), years after it (if a settlement includes a negotiated entry date), or close to expiration (if neither party wins convincingly and a settlement reflects the statistical distribution of litigation outcomes). Merck’s Januvia illustrates the settlement dynamic precisely. The primary compound patent expired in early 2023 with pediatric exclusivity, but the Orange Book also lists a salt and polymorph patent expiring in May 2027. Merck settled with 25 different generic companies, allowing them to enter in May 2026 — a date that the patent expiration date, whether from the Orange Book or PAT-INFORMED, would never have predicted.
PAT-INFORMED has no ANDA litigation data. It has no Paragraph IV certification tracking. It has no settlement monitoring. For U.S. competitive intelligence, it is a patent listing without the legal context that determines when those patents actually stop protecting the market.
PAT-INFORMED vs. MedsPaL: Choosing the Right Tool for LMIC Procurement
For procurement analysis in low- and middle-income countries, the comparison between PAT-INFORMED and MedsPaL is more nuanced than a simple recommendation. Each database has genuine strengths and specific gaps, and sophisticated procurement analysts use both.
MedsPaL’s Data Sourcing Model: Why Public Records Are More Reliable for Access Questions
MedsPaL, operated by the Medicines Patent Pool since its 2016 launch, sources its data primarily from national and regional patent offices. It also incorporates licensing information from public licensing agreements and data exclusivity information from national regulatory authorities. Unlike PAT-INFORMED, MedsPaL is designed specifically to identify opportunities for generic procurement, which means it actively seeks out the same information that patent holders have an incentive to suppress: patent withdrawals, expired patents in specific countries, territories where no patent was ever filed, and existing voluntary licenses that permit generic supply.
The 2024 relaunch of MedsPaL added the ability to save searches and set up email notifications for changes in patent status — a feature that reflects how practitioners actually use these tools, since patent status changes over time as patents expire, get challenged, or get withdrawn.
PAT-INFORMED’s Coverage Advantage: More Diseases, More Companies (In Theory)
PAT-INFORMED covers six therapeutic areas with submission from 20 major originator companies, which in principle provides broader coverage than MedsPaL for certain product categories. MedsPaL focuses on HIV, tuberculosis, hepatitis C, COVID-19, and essential medicines — a narrower scope aligned with MPP’s public health mission. For a procurement agency managing a broader formulary that includes cardiovascular drugs or diabetes therapies not on the WHO Essential Medicines List, PAT-INFORMED’s coverage is wider.
The complication, as the MSF brief documents, is that broader coverage built on voluntary, unverified self-disclosure by the patent holders is not the same as reliable broader coverage. The database may cover more therapeutic areas while being less accurate in each of them than a more narrowly scoped database built on independent public records.
Using PAT-INFORMED and MedsPaL Together: A Practical Protocol
For a procurement agency analyzing whether a medicine is available for generic procurement in a specific country, a reasonable protocol uses both tools in sequence. Start with MedsPaL to establish the baseline from public patent office records and identify any existing voluntary licenses. Cross-reference with PAT-INFORMED to catch any patents disclosed by the originator company that may not yet have been captured by the national patent office search. Where the databases disagree, treat the discrepancy as a flag requiring independent legal verification rather than defaulting to either source.
This protocol reflects how the database operators themselves describe the relationship. WIPO’s official PAT-INFORMED FAQs state that MedsPaL and PAT-INFORMED are both tools that procurement agencies can use to gather information — they are not alternatives but inputs into a broader analysis. The distinction that matters is between using either database as a starting point for further inquiry (appropriate) versus using either database as a terminal determination of patent status (inappropriate).
The Biosimilar Gap: Why PAT-INFORMED Cannot Help With Biologic LOE Analysis
PAT-INFORMED covers small-molecule drugs only. Biologic drugs — the monoclonal antibodies, fusion proteins, and other large-molecule therapeutics that now dominate pharmaceutical revenue — are structurally absent from the database. This is not a temporary gap; the database’s design philosophy for small molecules, based on linking an INN to a patent family, does not translate cleanly to biologics, where the patent landscape operates through a different statutory framework and the concept of “loss of exclusivity” involves interchangeability designations that have no analog in small-molecule generics.
Biosimilar Patent Challenges: How the BPCIA Pathway Changes LOE Analysis
For biologics in the U.S. market, loss of exclusivity analysis centers on the Biologics Price Competition and Innovation Act (BPCIA) framework, which provides 12 years of reference product exclusivity from the date of biologic licensure, plus a potential six-month pediatric exclusivity extension. Patent challenges proceed through the BPCIA’s “patent dance” process under 42 U.S.C. § 262(l), a structured exchange of manufacturing and patent information between the reference product sponsor and the biosimilar applicant.
Humira (adalimumab) is the most analyzed biologic LOE in the industry’s recent history and illustrates why PAT-INFORMED offers nothing for this analysis. AbbVie’s 12-year BPCIA exclusivity expired in 2023. But a secondary patent estate of over 130 U.S. patents — formulation patents, manufacturing process patents, device patents, and method-of-use patents — required AbbVie to negotiate individual settlement agreements with each biosimilar developer. Every major biosimilar competitor received a negotiated launch date rather than entering at BPCIA exclusivity expiration. The effective market entry dates were determined by private commercial settlements, not by any publicly searchable patent database. PAT-INFORMED provides no visibility into any element of this process.
The 12-Year BPCIA Exclusivity and Pediatric Extension: What LOE Models Must Include
For a biologic reference product, the correct LOE date calculation requires: the actual BLA first-licensure date (not the current holder’s commercial launch date, which may differ); whether pediatric exclusivity was granted (adding six months to the 12-year clock); the composition patent expiration; the secondary patent estate; and the litigation and settlement status with each biosimilar applicant. No free public database captures all five of these inputs. DrugPatentWatch’s tracking of BPCIA litigation and biosimilar entry timelines provides structured aggregation of the Orange Book and Purple Book data, PACER court filings, and biosimilar developer activity, which is why professional LOE analysts in the biologic segment use it rather than PAT-INFORMED.
What Evergreening Means for LOE Dates — and Why PAT-INFORMED Doesn’t Track It
Patent evergreening is the practice of filing successive patents on modified versions of a drug — new formulations, new delivery devices, new salt forms, new combinations, new methods of use — to extend effective market exclusivity beyond the expiration of the primary composition of matter patent. Evergreening is legal under current U.S. and international patent law. It is also among the most significant sources of error in LOE date estimates that rely on primary compound patent expiration as a proxy for market entry timing.
Secondary Patents and the Device Patent Problem: How Inhalers Stay Protected Long After the API Patent Expires
Research published in PLOS ONE examined 49 medicine/device combination products, primarily inhalers, and found that 90% had unexpired device patents even after the medicine patent expired. For 14 products, the device patent was the only unexpired patent. Comparing the last-to-expire device patent against the last-to-expire active ingredient patent, the median additional protection from device patents alone was 4.7 years, with a range of 1.3 to 15.2 years. A generic or biosimilar developer targeting an inhaled corticosteroid that anchors its LOE analysis to the API patent expiration — which is what PAT-INFORMED’s INN-based search tends to surface — may be 10 years off in estimating when competition becomes legally permissible.
PAT-INFORMED focuses on “key patents” for each product, with companies determining what “key” means. That determination is made by the patent holder. It is unlikely that a company voluntarily designates its own device or formulation patents as “key” in a way that alerts procurement agencies to the additional years of protection those patents provide.
Polymorph Patents, Salt Form Patents, and Lifecycle Management: Recognizable but Invisible in PAT-INFORMED
The pharmaceutical industry’s lifecycle management toolkit — extended-release formulations, combination products, new salt forms, polymorph patents, patient support programs embedded in device IP — creates patent landscapes that can keep branded drug revenue protected well beyond the nominal compound patent expiry. Merck’s Januvia again: the primary compound patent expired, but a salt and polymorph patent expiring years later remained listed in the Orange Book, giving Merck substantial leverage in settlement negotiations with generic companies.
A PAT-INFORMED search for sitagliptin would not tell an analyst which patents were most defensible, which were most likely to be challenged, or what settlement timeline to anticipate based on the current ANDA landscape. It provides a list of granted patents, sorted by country. Translating that list into a probability-weighted LOE date requires analysis that the database is not designed to support.
DrugPatentWatch as a Complement to PAT-INFORMED: What Commercial Intelligence Adds
For pharmaceutical companies, generic manufacturers, institutional investors, and supply chain teams tracking U.S. and global LOE timelines, DrugPatentWatch addresses the structural gaps in PAT-INFORMED and the Orange Book by aggregating data from multiple primary sources and linking it to actionable competitive intelligence. Where PAT-INFORMED provides company-reported patent lists and the Orange Book provides FDA-listed patents without litigation context, DrugPatentWatch maps the full landscape: Orange Book patents with PTA and PTE adjustments, regulatory exclusivities, Paragraph IV filing history, ANDA applicant identities, first-filer status determinations, 30-month stay timelines, court decision outcomes, and settlement agreements.
How DrugPatentWatch Tracks 180-Day Exclusivity Forfeiture: The Detail That Changes Generic Launch Windows
The 180-day first-filer exclusivity is the most commercially valuable period in a generic drug’s lifecycle, capturing 60% to 80% of the product’s total lifetime generic value in many cases. But the forfeiture rules are complex. A first filer can lose the 180-day exclusivity through failure to obtain tentative approval within 30 months of ANDA submission, through failure to market within a specified period, or through certain types of settlements. When a first filer forfeits its exclusivity, the market opens to all other approved ANDA filers, compressing the competitive timeline unexpectedly.
DrugPatentWatch tracks first-filer eligibility status and known forfeiture events, which enables supply chain analysts to identify products where the first-to-market generic window may open earlier than the first filer’s nominal entry date — intelligence that PAT-INFORMED cannot provide because PAT-INFORMED has no awareness of the ANDA process at all.
Global Patent Coverage in 134 Countries: Why Scale Matters for Multi-Market LOE Analysis
DrugPatentWatch covers patent and exclusivity data across 134 countries, allowing analysts to identify markets where a competitor holds weak or absent patent protection while the home market remains locked. This geographic arbitrage analysis — finding countries where generic or biosimilar entry is permissible while other markets remain protected — is a core competency for global pharmaceutical business development that PAT-INFORMED’s country-by-country INN search approach supports only superficially.
For supply chain teams managing a large formulary across multiple regions, the ability to monitor LOE events automatically through configured alerts — rather than manually searching individual INNs across multiple databases — represents a structural efficiency gain. Assembling the four inputs needed for accurate U.S. LOE analysis (Orange Book patents with PTA/PTE adjustments, regulatory exclusivity periods, Paragraph IV filing status, and first-filer eligibility) across hundreds of drugs is not a one-time project. ANDA filings arrive continuously, litigation outcomes change timelines, and first-filer forfeitures can open markets unexpectedly.
The Five Inputs for an Accurate LOE Date: A Step-by-Step Framework
Whether you use PAT-INFORMED as a starting point or not, an accurate U.S. drug loss-of-exclusivity determination requires five distinct inputs, each from a different primary source.
Step 1: Orange Book Patent Listing — The Starting Point, Not the Endpoint
Search the FDA Orange Book by brand name or active ingredient to identify all listed patents and their associated expiration dates. Note that these expiration dates may not reflect PTA adjustments accurately and may not reflect PTE grants. Identify which patents are composition-of-matter patents, formulation patents, and method-of-use patents, since the type of patent determines how it affects generic entry timing under ANDA law.
Step 2: USPTO Patent Center — PTA, PTE, and Maintenance Fee Status
For each Orange Book-listed patent, search the USPTO Patent Center to verify the actual expiration date after PTA, and check whether a PTE has been applied. The USPTO maintains a separate Patent Term Extension database. Also check maintenance fee payment status: a patent whose maintenance fees have lapsed is expired regardless of the statutory term date, and this information does not update instantaneously in the Orange Book. Lapsed maintenance fees are one of the most consistently missed sources of early LOE dates in formulary management.
Step 3: FDA Exclusivity Database — The Non-Patent Protection Layer
Check the Orange Book’s exclusivity section to identify any NCE, Orphan, three-year clinical investigation, or pediatric exclusivity periods. Verify whether pediatric exclusivity applies, since it extends both the patent and regulatory exclusivity timelines simultaneously. The FDA updates this section after each approval decision. Compare the final regulatory exclusivity expiration date against the final patent expiration date; whichever is later defines the earliest permissible generic ANDA approval date.
Step 4: FDA Paragraph IV Certification List — Who Has Filed and When
The FDA publishes the Paragraph IV Certification List, updated as certifications are received, identifying all substantially complete ANDAs that contain Paragraph IV certifications. This list shows which companies have challenged which patents, the date of certification, and whether 180-day first-filer exclusivity is at issue. A drug that appears to have years of remaining patent protection but already has multiple Paragraph IV certifications on file is in active litigation, and the court calendar matters more than the patent expiration date for estimating actual generic entry.
Step 5: PACER and Settlement Monitoring — The Litigation and Deal-Making Layer
Check the PACER federal court database for active patent infringement cases filed in response to Paragraph IV certifications. Identify the courts (predominantly the District of Delaware and the District of New Jersey for Hatch-Waxman cases), the litigation status, and whether any settlements have been reported. Litigation settlements often include negotiated commercial launch dates that define the effective LOE date regardless of patent expiration.
Where PAT-INFORMED Fits in This Five-Step Framework
PAT-INFORMED contributes to Step 1 only, and only for products covered by its therapeutic area scope and only for countries where the patent-holding company chose to submit data. For the other four steps — PTA/PTE verification, regulatory exclusivity tracking, Paragraph IV monitoring, and litigation analysis — PAT-INFORMED provides nothing. For non-U.S. markets, PAT-INFORMED’s contribution to Step 1 carries the additional caveats about completeness and potential omission bias documented in the MSF brief.
PAT-INFORMED for Developing Country Patent Analysis: A Realistic Assessment
The most defensible use case for PAT-INFORMED is the one it was explicitly designed for: helping procurement agencies in developing countries establish a preliminary understanding of which medicines are under patent in their jurisdictions, as a first step before commissioning more thorough independent analysis for high-stakes procurement decisions.
Association Africaine des Centrales d’Achats de Médicaments Essentiels (ACAME): The Target User
Issake Sondé, the Directeur Exécutif of ACAME — the African Association of Procurement Centers for Essential Medicines — stated at PAT-INFORMED’s launch that procurement agencies in developing countries need patent status information to purchase “the best quality medicines at the most affordable prices.” For member countries of ACAME procuring medicines through centralized public health programs, PAT-INFORMED addresses a genuine gap in available tools.
A procurement officer at a ministry of health in a country with limited IP law expertise who previously had no free, INN-searchable resource for patent status information now has one. Whether that resource is complete and accurate is a separate question from whether it is better than nothing. For low-stakes initial scoping — “Is this medicine generally under patent or generally off-patent globally?” — PAT-INFORMED provides useful preliminary orientation. For high-stakes procurement decisions — “Can we legally procure the generic version of this medicine in our country right now?” — PAT-INFORMED requires independent verification and should not be treated as a terminal determination.
The 30% Procurement Cycle Reduction Claim: What It Actually Measures
i+solutions projected a 30% reduction in procurement cycle time from using PAT-INFORMED. That figure refers to the time spent on initial patent status research — a phase that, in the absence of PAT-INFORMED, required manual searches across national patent registers and bilateral inquiries to patent holders. PAT-INFORMED consolidates that initial research into a single searchable interface. It does not reduce the time required for independent legal verification in high-stakes cases, and it does not eliminate the need for that verification. It reduces the time to get to the starting line for due diligence, not the time to complete it.
Financial Implications of Using the Wrong LOE Date: Case Studies
The industry commonly describes the pharmaceutical patent cliff as a slow-motion revenue event. In practice, for small-molecule blockbusters entering multi-source generic competition, it is fast. The typical revenue erosion pattern after the first generic launch is an 80-90% decline in brand unit share within the first year of multi-source competition. The branded product goes from a monopoly to a residual market share within 12 months. Getting the LOE date wrong by even six months has quantifiable financial consequences.
Generic Manufacturer: Entering Too Early Versus Too Late
A generic company that misreads a PAT-INFORMED-sourced patent expiration date and launches a product before all blocking patents and regulatory exclusivities have cleared faces immediate patent infringement litigation. Depending on the case, the remedies can include a preliminary injunction that stops sales, disgorgement of profits, and the reputational damage of a high-profile launch failure. At-risk launches are a legitimate strategic choice in some circumstances, but they require a deliberate litigation risk assessment that PAT-INFORMED is not equipped to support.
The reverse error — entering too late because PAT-INFORMED listed a patent that was actually withdrawn, invalidated, or never filed in the relevant jurisdiction — is equally costly. A generic manufacturer that misses the first-mover period by six months because it over-relied on inflated patent coverage data in a voluntary self-reported database may never fully recover the lost margin. The 180-day first-filer exclusivity window is typically the most profitable period in a generic product’s lifecycle.
Pharmaceutical Investor: The Merck Januvia Example Revisited
An investor modeling Merck’s Januvia (sitagliptin) revenue timeline solely from patent expiration data — whether from PAT-INFORMED, the Orange Book, or any other source — would have reached a structurally incorrect conclusion about the 2026 competitive landscape. The primary compound patent expired in early 2023. A salt and polymorph patent expiring in May 2027 is listed in the Orange Book, suggesting continued protection. But Merck settled with 25 generic companies, licensing entry in May 2026. The settlement date, not the patent date, is the operative LOE.
This is not an unusual outcome. Settlement is the dominant resolution mechanism for Hatch-Waxman Paragraph IV litigation. A database that tracks only patent expiration dates and ignores the settlement landscape will systematically overestimate the duration of branded exclusivity for drugs with active litigation. PAT-INFORMED sits at the far end of this spectrum — it does not track litigation at all, making it particularly unsuitable for revenue modeling in the U.S. market.
Supply Chain Procurement: Orphan Drug Exclusivity as the Missed Variable
Supply chain teams managing formularies that include specialty drugs with Orphan Drug designations routinely underestimate supply concentration risk when they anchor LOE analysis to patent expiration dates without checking regulatory exclusivity. A drug with an Orphan Drug Exclusivity designation receives seven years of market protection for the orphan indication regardless of patent status. If the compound patent expires before the Orphan Drug Exclusivity period, competition remains blocked for the remaining exclusivity term even though the patent is gone. PAT-INFORMED does not capture this distinction.
Patent Thickets, Secondary Patents, and the LOE Dates That No Single Database Can Give You
The standard framing of pharmaceutical patent protection as a single expiry event is analytically wrong for most blockbuster drugs. In practice, a commercially successful small molecule is protected by a layered stack of patents: a primary composition of matter patent covering the active ingredient, followed by formulation patents, method-of-use patents, polymorph and salt form patents, dosing regimen patents, metabolite patents, and — for combination products — additional patents on each component and the combination. The clinical and commercial development of a successful drug generates successive patent filings across multiple dimensions, each adding to the stack.
The consequence is that the expiration of the primary compound patent — which is typically the oldest, most legally vulnerable, and most prominently tracked patent in any database — does not end exclusivity. It begins the negotiating phase, during which the brand and generic manufacturers assess the secondary estate, file Paragraph IV certifications against the remaining patents, and eventually reach settlements that define the real market entry date. The compound patent expiry date is the opening bid in that negotiation, not the final answer.
AbbVie’s Humira Strategy: The Secondary Patent Estate as the Real Moat
AbbVie’s Humira (adalimumab) is the most cited example of secondary patent estate strategy in the industry because the scale is exceptional. After the initial adalimumab compound patent expired and BPCIA reference product exclusivity ended in 2023, AbbVie had assembled over 130 U.S. patents covering formulations, concentrations, autoinjector devices, manufacturing processes, and methods of use. Each biosimilar developer had to assess which of those patents applied to its specific biosimilar formulation and device, negotiate privately with AbbVie, and reach individual settlement agreements with negotiated launch dates.
Amgen’s Hadlima launched in the U.S. market in 2023. Sandoz’s Hyrimoz followed. Samsung Bioepis’s Hadlima and Fresenius Kabi’s Idacio each had their own dates. The effective LOE for Humira in the U.S. market was not a single date — it was a staged sequence of biosimilar launches determined by individual settlements, each at a different negotiated entry date. No patent database — not PAT-INFORMED, not the Purple Book, not the FDA’s biosimilar tracking resources — captures the settlement dates that produced the actual competitive entry calendar.
Eliquis (apixaban), the factor Xa inhibitor developed by BMS and Pfizer, illustrates the formulation patent extension strategy for small molecules. The primary compound patent on apixaban faced Paragraph IV challenges from multiple ANDA filers. BMS and Pfizer successfully defended several listed patents in litigation, and the compound patent expiry — combined with formulation patents covering the specific tablet formulation used in the approved product — created a layered protection structure that generic entrants had to navigate through both litigation and design-around strategies.
A procurement agency using PAT-INFORMED to analyze apixaban’s patent status would receive a list of patents disclosed by BMS in the applicable therapeutic category (cardiovascular). Whether that list included the specific formulation patents most likely to be litigated, whether it reflected the current litigation status against ANDA filers, and whether any settlement terms had been reached — none of this would appear. The procurement agency would have a patent list, not an LOE date.
What Counts as a ‘Key Patent’ in PAT-INFORMED: The Definitional Problem
PAT-INFORMED states that it provides information about “key patents” for each medicine. The FAQs do not define what “key” means or who determines it. In patent litigation, the distinction between key and non-key patents matters enormously — a weak formulation patent that a generic company could easily design around is not equivalent to a strong compound patent that covers the only commercially viable form of the active ingredient. PAT-INFORMED’s list of “key patents” presents all listed patents with equal visual weight, giving no indication of which patents are broad versus narrow, which are most likely to be challenged, or which would actually block market entry if challenged and upheld.
This is not a design flaw unique to PAT-INFORMED — the FDA Orange Book has the same limitation, listing patents without evaluating their strength. But PAT-INFORMED compounds the problem by also giving companies discretion over which patents to list in the first place, so the list may be neither complete nor representative of the patents that actually matter commercially.
The IRA’s Price Negotiation Program and How It Changes LOE Calculations After 2026
The Inflation Reduction Act of 2022 introduced a Medicare drug price negotiation program that changes the LOE analysis framework for high-revenue drugs. Under the program, the U.S. government can negotiate prices for high-expenditure Medicare Part B and Part D drugs that lack generic or biosimilar competition. The negotiated prices take effect regardless of patent status, creating a mechanism that caps brand pricing while patents are still in force for certain drugs. This affects the financial incentive structure for brand manufacturers to maintain secondary patent protection on drugs subject to negotiation, and it creates a new category of LOE analysis — the negotiated price date — that has no analog in any patent database.
Small-Molecule Drugs: The 9-Year vs. 13-Year IRA Threshold and Its LOE Implications
The IRA distinguishes between small-molecule drugs and biologics for negotiation eligibility. Small-molecule drugs become eligible for negotiation nine years after initial FDA approval; biologics become eligible at 13 years. This 9-year threshold is shorter than the standard small-molecule protection window for blockbuster drugs with Patent Term Extensions and secondary patent estates, meaning that under the IRA, a brand manufacturer may face negotiated pricing while the compound patent and secondary patents remain in force.
The financial impact of this timeline is material. A drug with $5 billion in annual U.S. revenue that becomes subject to IRA negotiation at year nine, while secondary patents are expected to block generic entry until year fourteen, faces a revenue reduction that does not appear as “LOE” in traditional patent-expiry analysis but produces comparable financial consequences. LOE models built before the IRA’s price negotiation provisions took effect are structurally incomplete for post-2026 analysis. PAT-INFORMED, a patent database with no regulatory policy layer, contributes nothing to this dimension of pharmaceutical revenue modeling.
How Procurement Agencies in Practice Use Patent Databases: Fieldwork Evidence
Understanding how procurement professionals actually use PAT-INFORMED in practice requires looking at the evidence from procurement agencies in the field rather than the promotional materials from WIPO and IFPMA. The most useful evidence comes from practitioners like the i+solutions team, which manages medicines procurement for multiple developing country health systems and has explicitly evaluated PAT-INFORMED’s utility.
The i+solutions Experience: PAT-INFORMED as a Time-Saver, Not a Decision-Maker
Wesley Kreft of i+solutions described PAT-INFORMED as having the potential to reduce procurement cycle times by 30% — a figure that refers specifically to the initial research phase of identifying patent status. The 30% figure is for cycle time reduction on the research phase, not for the overall procurement process. i+solutions, as an organization with dedicated medicines access expertise and IP advisory capacity, uses PAT-INFORMED as one input among several and does not make procurement decisions based on PAT-INFORMED data alone.
For a smaller national procurement agency with limited IP advisory capacity, the temptation to treat PAT-INFORMED as a terminal data source is higher — and the consequences of doing so are more serious. A procurement officer in a country where the regulatory and legal framework for engaging with patent disputes is underdeveloped may lack both the expertise to identify when PAT-INFORMED data is misleading and the institutional support to commission independent legal verification for every procurement decision. The database’s usefulness correlates inversely with the analytical sophistication of the user: sophisticated users benefit from the time savings on initial research; less sophisticated users risk being misled by incomplete data.
MSF’s Internal Procurement Practice: Why the Organization That Criticized PAT-INFORMED Still Uses It
MSF Access Campaign, which submitted the technical brief criticizing PAT-INFORMED to WIPO’s Standing Committee on Patents, continues to engage with the database as a starting point for patent status inquiries. The critique was not that the database should not exist but that it should not be presented as an authoritative or independent source of patent information, and that WIPO’s institutional imprimatur creates a false impression of neutrality for data that reflects the commercial interests of its contributors.
Organizations with the analytical capacity to identify PAT-INFORMED’s limitations can use it profitably as a first-pass research accelerator. The concern is for procurement agencies without that capacity — particularly smaller national health authorities in low- and middle-income countries with no in-house IP expertise — that may be structurally positioned to over-rely on the database precisely because it carries WIPO’s name and is presented as a solution to the medicines patent information gap.
The Role of National Patent Registers in Building Country-Specific LOE Analysis
For any country with an active pharmaceutical market, the definitive source of patent status information is the national patent office’s register. National registers vary enormously in accessibility, completeness, and search functionality, but they share a critical characteristic that PAT-INFORMED lacks: they are maintained by an independent government authority and reflect the actual legal status of granted patents in that jurisdiction.
Health Canada’s Patent Register: The Canadian Model for Linking Patents to Products
Health Canada maintains the Patent Register under the Patented Medicines (Notice of Compliance) Regulations — Canada’s equivalent of the U.S. Orange Book. The register provides an alphabetical listing of medicinal ingredients and their associated patents, expiry dates, and related information. Generic manufacturers in Canada seeking to challenge a listed patent file a Notice of Allegation under the PM(NOC) Regulations, triggering the Canadian equivalent of the Hatch-Waxman 30-month stay. For any analysis of Canadian drug LOE dates, the Health Canada Patent Register is the authoritative primary source; PAT-INFORMED does not replicate it.
The European Patent Office’s Espacenet: Identifying International Patent Filings Not in PAT-INFORMED
The European Patent Office’s Espacenet database provides free access to European patent applications and grants, including international Patent Cooperation Treaty (PCT) applications. For analysts searching for patents on a specific drug compound that are not disclosed in PAT-INFORMED — either because the company did not participate or because it chose not to disclose specific patents — Espacenet is a valuable cross-reference for European patent families. Combining an Espacenet search by assignee name and INN with a PATENTSCOPE PCT search provides coverage of European and international patent filings that PAT-INFORMED may or may not reflect.
National Patent Office Variability in Developing Countries: Where PAT-INFORMED Fills a Genuine Gap
Many national patent offices in low- and middle-income countries have limited online search capabilities, inconsistent filing and examination records, and no mechanism for linking granted patents to specific approved drug products. For a procurement agency in these countries, the practical alternative to PAT-INFORMED is not a more sophisticated national database — it is commissioning bilateral patent searches with local IP counsel at significant cost and delay for every product on the formulary. PAT-INFORMED’s contribution, in this context, is to provide a first-pass indication of whether patents exist, even if that indication comes from the patent holder and is subject to the completeness caveats discussed above.
The critical gap is the absence of a WIPO-maintained independent patent database that draws from national patent office records — the resource that the UN Secretary-General’s High-Level Panel on Access to Medicines recommended. PAT-INFORMED was not the initiative that panel called for; it was an industry-designed alternative that provides voluntary, unverified disclosures rather than independent, consolidated government records. That distinction matters for the trust procurement agencies should place in the results.
Lifecycle Management Strategies That Move LOE Dates: What Analysts Must Track Beyond Patents
Pharmaceutical companies have multiple tools for extending effective exclusivity beyond the primary patent expiry. Understanding drug LOE dates requires tracking all of them, not just the patent expiry that appears in databases.
New Indication Approvals and Three-Year Clinical Investigation Exclusivity
When a pharmaceutical company submits a supplemental NDA containing reports of new clinical investigations that are essential for the new approval, the FDA grants three years of additional exclusivity for the new indication or formulation. This exclusivity does not protect the entire product — it protects only the aspect of the drug covered by the new clinical data — but it can block generic approval for that specific use. For drugs with multiple indications, the three-year clinical investigation exclusivity from a recent supplemental approval can shift the effective LOE date for a portion of the revenue base.
Authorized Generic Agreements: How Brand Companies Compete With Their Own Generics
An authorized generic is a copy of a brand-name drug that the brand manufacturer licenses to a generic company, or sells itself, at a price below the brand but above the typical multi-source generic level. Authorized generics launch simultaneously with the first-filer generic, splitting the 180-day exclusivity revenue and reducing the first-filer’s incentive to challenge additional patents aggressively. The presence of an authorized generic agreement in a market can compress generic competition economics and affect which ANDA filers continue developing products — changing the supply landscape even after the nominal LOE date arrives.
REMS Programs: When Safety Requirements Create De Facto Supply Restrictions
Risk Evaluation and Mitigation Strategies (REMS) are FDA-mandated programs for drugs with serious safety risks that impose distribution restrictions, patient enrollment requirements, or healthcare provider training obligations. Some REMS programs restrict which pharmacies can dispense a drug or require patients to meet specific eligibility criteria before receiving a prescription. These restrictions can create supply chain complexity that persists after LOE, limiting the effective competitive landscape even when generics are technically approved.
For supply chain analysts modeling generic market dynamics post-LOE, REMS programs on branded products require special attention. A generic that obtains an abbreviated ANDA approval still must comply with the REMS, and the operational burden of establishing REMS-compliant distribution channels can delay effective market entry for new generic entrants beyond the ANDA approval date. PAT-INFORMED has no awareness of REMS programs; they represent a category of post-LOE supply constraint that patent-only analysis cannot identify.
Generic Drug Supply Chain Planning Around LOE: The Practical Intelligence Requirement
For supply chain teams, the operational challenge of LOE management is not primarily about knowing the exact LOE date in advance — it is about building the procurement infrastructure, alternative supplier relationships, and formulary transition protocols to execute an efficient switch when competition arrives. That operational planning requires patent intelligence calibrated to supply chain risk, not just market entry timing.
Single-Source Generics and the Supply Concentration Risk Post-LOE
Not all post-LOE markets develop into competitive multi-source generics markets quickly. For drugs with complex manufacturing requirements — extended-release formulations, narrow therapeutic indices, specialized API synthesis — the number of ANDA applicants may be small, and the first-to-market generic may retain a de facto near-monopoly for months or years after the brand’s exclusivity ends. Supply chain teams that model post-LOE procurement assuming rapid price erosion and multiple competing suppliers may be as wrong as those that mis-identify the LOE date itself.
DrugPatentWatch’s tracking of ANDA applicant identities and approval status enables analysts to project the likely number of generic suppliers entering a market at LOE, which is necessary for accurate post-LOE pricing and procurement volume assumptions. For drugs with only one or two ANDA applicants, the supply concentration risk post-LOE may be comparable to the supply concentration risk while the drug is still branded.
API Supplier Geography and the Regulatory Filing Chain
The generic supply chain for small-molecule drugs typically extends back through a Drug Master File (DMF) holder — the active pharmaceutical ingredient manufacturer — whose manufacturing process is referenced in the generic manufacturer’s ANDA. Supply chain disruptions in the API supply chain can affect brand and generic availability simultaneously, regardless of patent status. For supply chain risk management, LOE date intelligence needs to be layered with supplier geography intelligence and regulatory filing chain analysis. None of these dimensions appear in PAT-INFORMED.
PAT-INFORMED’s Therapeutic Area Gaps: What Oncology and Rare Disease Analysts Cannot Get from the Database
PAT-INFORMED nominally covers oncology, one of the six designated therapeutic areas. In practice, the oncology coverage is limited to small-molecule oncology products submitted by the 20 participating companies. Targeted therapies developed by non-participating companies, cell and gene therapies, antibody-drug conjugates, and the growing class of radioligand therapies are absent. Oncology is the highest-revenue pharmaceutical category globally and the one with the most complex, rapidly evolving patent landscapes. The database’s coverage of the category is thin relative to the category’s commercial significance.
Why Rare Disease Drug LOE Analysis Requires More Than PAT-INFORMED
Rare disease drugs present a specific analytical challenge. Orphan Drug Exclusivity creates seven years of market protection that runs independently of patents. The Rare Pediatric Disease Priority Review Voucher program creates a transferable asset worth hundreds of millions of dollars that affects corporate strategy without appearing in any patent database. The limited population sizes of rare diseases mean that generic entry economics are often unfavorable even after exclusivity expires, creating situations where nominal LOE does not produce actual competition. None of this appears in PAT-INFORMED.
How to Search PAT-INFORMED Correctly: Avoiding the Most Common Analytical Mistakes
If you do use PAT-INFORMED, these are the specific practices that reduce the likelihood of analytical error.
Always Search by INN, Not Brand Name
PAT-INFORMED’s search function operates on International Nonproprietary Names. A search for “Harvoni” will likely return no results; a search for “ledipasvir” may. Using brand names instead of INNs is the most common user error and produces misleading null results. Verify the correct INN using the WHO INN database before searching PAT-INFORMED.
Interpret Null Results as Ambiguous, Not as Patent-Free
A PAT-INFORMED search that returns no patents for a medicine in a specific country does not mean the medicine is patent-free in that country. It may mean the company chose not to disclose patents there, did not file patents there, has patents pending rather than granted, or simply does not participate in PAT-INFORMED. The database FAQs acknowledge that absence of information cannot be taken to mean no patents exist. This caveat is important enough that analysts should treat null results with the same skepticism they would apply to positive patent listings.
Cross-Reference Every Result with an Independent Source
For any procurement or investment decision that depends on patent status, use PAT-INFORMED as a first-pass screen, then cross-reference with MedsPaL (for access-focused LMIC analysis), the FDA Orange Book (for U.S. market analysis), or the relevant national patent office database. For high-value decisions, commission an independent freedom-to-operate analysis from an IP law firm. PAT-INFORMED is not a substitute for any of these; it is a preliminary sorting tool.
Check Whether the Participating Company Is the Product’s Actual Patent Holder
For drugs that have been licensed, acquired, or divested, the company currently marketing the product may not be the same company that holds the patent. Gilead Sciences, for example, has acquired multiple HIV and hepatitis C patent portfolios. The originating company may no longer be a PAT-INFORMED participant even if the drug is covered. Verify the patent assignee for each listed patent using PATENTSCOPE or the USPTO before relying on the company’s PAT-INFORMED submission as comprehensive.
What PAT-INFORMED’s Expansion Plans Mean for Future Coverage
WIPO and IFPMA have stated that PAT-INFORMED will expand to cover all therapeutic areas and explore the inclusion of complex therapeutics (biologics) in a second phase. That expansion was announced in the 2018 launch materials. As of mid-2026, the six original therapeutic areas remain the database’s core scope, and no timeline for biologic inclusion has been confirmed publicly.
Will Expanding Coverage Fix the Self-Reporting Problem?
Expanding therapeutic area coverage without changing the data sourcing model does not address the fundamental limitation. A database covering all small-molecule drugs across all therapeutic areas, with data still provided voluntarily by the patent-holding companies without independent verification, would be a larger version of the current database’s structural problem rather than a solution to it. The criticism in the MSF brief applies to the sourcing model, not the coverage scope. Broader coverage with the same voluntary, unverified sourcing produces more extensive data with the same reliability caveats.
An expansion that includes independent verification mechanisms, mandatory disclosure for participating companies, and integration of licensing data would represent a materially improved tool. The current initiative structure, controlled by IFPMA on behalf of its member companies, creates structural disincentives to those improvements.
The Biologic Coverage Gap: When Will PAT-INFORMED Be Useful for Biosimilar Analysis?
Given the complexity of biologic patent landscapes — the patent dance under BPCIA, the multiple overlapping patent families, the interchangeability designation process, the private settlement structure that determines most U.S. biosimilar launch dates — a PAT-INFORMED-style voluntary disclosure model would face significant challenges in producing reliable LOE dates for biologics even if the expansion proceeds. AbbVie’s Humira biosimilar case demonstrates that biologic LOE analysis requires tracking over 130 individual patents and a series of confidential settlement negotiations, not just a list of granted patents by country.
Timeline: Key Dates in PAT-INFORMED’s History and Coverage Evolution
2003: Médecins Sans Frontières publishes “Drug Patents Under the Spotlight,” the first medicines patent database for the global health community. It becomes the intellectual predecessor to MedsPaL.
September 2018: WIPO and IFPMA launch PAT-INFORMED with 20 participating companies, covering HIV/AIDS, cardiovascular diseases, diabetes, hepatitis C, oncology, and respiratory conditions, plus WHO Essential Medicines List products.
October 2016: MedsPaL launches, operated by the Medicines Patent Pool, focusing on HIV, hepatitis C, and tuberculosis.
December 2019: MSF and allied civil society organizations submit a technical brief to the WIPO Standing Committee on Patents documenting specific examples of incomplete, inaccurate, and potentially biased data in PAT-INFORMED.
2020: PAT-INFORMED reports coverage of 14,000+ individual patents for 600 patent families and 169 INNs.
May 2024: MPP launches a redesigned MedsPaL with saved searches, email notifications, improved mobile compatibility, and a new license information tab.
2026: PAT-INFORMED reports 18,900+ individual patents for 636 patent families. Second-phase expansion to all therapeutic areas and complex biologics has not been publicly dated.
Regulatory Exclusivity Around the World: Why Country-Specific LOE Dates Require More Than Patent Data
In the European Union, market exclusivity for pharmaceutical products is governed not by patent law alone but by Supplementary Protection Certificates (SPCs), which are regulatory instruments that extend the effective patent term for products that required regulatory approval before reaching market. An SPC can extend exclusivity for up to five years beyond the basic patent’s expiration, with a six-month pediatric extension available on top of that — meaning a compound patent expiring in 2025 might provide effective market protection through 2031 with a full SPC and pediatric extension.
Supplementary Protection Certificates in the EU: What They Are and Why PAT-INFORMED Misses Them
SPCs are not patents. They are granted by national IP offices in EU member states and the UK based on the first marketing authorization for the product in that territory. An SPC search requires checking the national IP office of each relevant EU member state, since SPC grants and expirations vary across the bloc and SPCs are not captured in PATENTSCOPE or in PAT-INFORMED’s standard database output. For any LOE analysis in the European market, SPC status is not optional — it is frequently the operative protection mechanism that extends exclusivity beyond the compound patent’s expiration date, and it is the layer most commonly missed by analysts relying on patent databases that cover only patents.
Japan, Canada, and Australia have analogous exclusivity mechanisms with their own specific rules and registration requirements. Canada’s Patent Register links patents to products for regulatory purposes under the Patented Medicines (Notice of Compliance) Regulations, providing a domestic equivalent of the Orange Book for the Canadian market that PAT-INFORMED does not replicate.
Data Exclusivity vs. Patent Protection: The Regulatory Barrier That Operates Independently
Data exclusivity protects the proprietary clinical data that supported a drug’s regulatory approval. During the data exclusivity period, a generic manufacturer cannot reference the innovator’s clinical data to support an ANDA or its equivalent in other jurisdictions, even if no patent is in force. In the U.S., the NCE data exclusivity period is five years. In the EU, it is eight years (six years of data exclusivity plus two years of market exclusivity under the 8+2+1 system). Data exclusivity periods can prevent generic market entry even after all relevant patents have expired, and they are invisible to any patent-only database including PAT-INFORMED.
What This Means for Generic Pharmaceutical Companies
A generic pharmaceutical company evaluating entry opportunities for a specific molecule in a specific country should not use PAT-INFORMED as a substitute for the regulatory and competitive intelligence process required to support an ANDA filing or its international equivalent. PAT-INFORMED provides a free, fast initial screen. The regulatory filing process requires a thorough patent landscape analysis, a freedom-to-operate opinion from qualified IP counsel, and a full review of the regulatory exclusivity landscape in each target market.
The competitive advantage in generic pharmaceutical development comes from identifying opportunities that competitors have not yet recognized and moving faster through the approval and launch process. A database that provides lagged, voluntary, unverified patent data from the patent holders themselves is not a source of competitive advantage. It is a starting point for analysts who then use primary sources — the Orange Book, the USPTO, PACER, MedsPaL, and commercial intelligence platforms like DrugPatentWatch — to build the actual analysis.
What This Means for Pharmaceutical Investors and Analysts
Revenue model accuracy in pharmaceutical investment analysis depends on correct LOE dates. An analysis that uses the nominal compound patent expiration as the LOE date — whether sourced from PAT-INFORMED, the Orange Book, or any other single-source database — will systematically overestimate brand revenue duration for drugs with secondary patent estates and underestimate brand revenue duration for drugs protected by regulatory exclusivities that extend beyond the final patent. The correct framework models the later of the final relevant patent and the final regulatory exclusivity, adjusted for settlement-based entry dates where Paragraph IV litigation is active.
For the U.S. pharmaceutical market specifically, between 2025 and 2030, the patent cliff 2.0 cycle is projected to expose between $200 billion and $400 billion in annual branded drug revenue to generic and biosimilar competition. The range itself reflects genuine analytical uncertainty about litigation outcomes, biosimilar entry timelines, and IRA price negotiation schedules. PAT-INFORMED, designed for procurement agencies in low- and middle-income countries, does not address any element of that analytical uncertainty for U.S.-focused investors.
What This Means for Hospital and Government Formulary Managers
Formulary managers in hospital systems and government payers benefit from LOE intelligence because it allows proactive tender planning for generic and biosimilar alternatives. PAT-INFORMED’s utility for this purpose varies by geography. For a hospital system or national health authority in a developing country managing procurement across a formulary that includes WHO Essential Medicines, PAT-INFORMED provides useful preliminary orientation at no cost. For a U.S. hospital system or government payer managing formulary strategy for branded drugs subject to Paragraph IV litigation and settlement-based entry timelines, PAT-INFORMED provides almost nothing of direct operational relevance.
Competitive Intelligence Use Cases for PAT-INFORMED: A Function-by-Function Audit
Rather than a binary yes-or-no answer to whether PAT-INFORMED is useful, the correct framework maps the database’s capabilities to specific professional functions and rates its adequacy for each. The following audit covers eight professional use cases and rates PAT-INFORMED’s adequacy for each, with notes on what it provides and what must be sourced elsewhere.
Use Case 1: Initial Scoping for Public Health Procurement in LMICs
Rating: Adequate as a starting point. PAT-INFORMED provides a free, INN-searchable resource that links approved medicines to patent data by country. For procurement agencies without access to more sophisticated tools and without in-house IP expertise, it provides preliminary orientation. It must be cross-referenced with MedsPaL and should not be treated as a terminal determination. For medicines not covered by the 20 participating companies’ voluntary disclosures, the database adds nothing and may create a false impression of a patent-free landscape through absence of results.
Use Case 2: U.S. Generic Market Entry Analysis
Rating: Inadequate. PAT-INFORMED provides no Paragraph IV certification data, no Orange Book regulatory exclusivity information, no PTA/PTE-adjusted patent expiry dates, no first-filer eligibility determination, and no litigation or settlement monitoring. All five of these inputs are required for accurate U.S. LOE and generic entry timing analysis. A generic company relying on PAT-INFORMED for U.S. market entry planning would be making decisions without the operative analytical layer.
Use Case 3: European Market LOE Analysis
Rating: Insufficient. PAT-INFORMED covers European patent grants but does not capture Supplementary Protection Certificates, which are the primary mechanism for extending pharmaceutical exclusivity in the EU beyond compound patent expiry. SPC status must be verified at each national IP office. The database also does not reflect the EU’s 8+2+1 data exclusivity framework. European LOE analysis requires a multi-source approach that begins with the compound patent identified in PAT-INFORMED or PATENTSCOPE and then layers SPC data from national IP offices and data exclusivity from the EMA’s marketing authorization database.
Use Case 4: Biologic and Biosimilar LOE Analysis
Rating: Not applicable. PAT-INFORMED covers only small-molecule drugs. For any biologic product, the database provides nothing. Biologic LOE analysis requires the Purple Book for BPCIA exclusivity dates, patent-specific analysis from PATENTSCOPE and the USPTO, BPCIA patent dance litigation tracking, and settlement monitoring.
Use Case 5: Pharmaceutical Investment Portfolio LOE Modeling
Rating: Inadequate as a standalone tool. Revenue cliff modeling for a pharmaceutical portfolio requires the settlement-adjusted, exclusivity-inclusive LOE dates that PAT-INFORMED cannot produce. Institutional investors using PAT-INFORMED as a primary patent data source for portfolio modeling would systematically misestimate the revenue impact of the patent cliff across all dimensions where secondary patents, regulatory exclusivities, and settlements diverge from primary compound patent expiry dates.
Use Case 6: Freedom-to-Operate Analysis for Biosimilar or Generic Development Programs
Rating: Inadequate as a standalone tool, useful as a preliminary screen. PAT-INFORMED can provide a first-pass inventory of patents to investigate further. An IP law firm conducting a full FTO analysis would then research each listed patent through the USPTO, assess claim scope, evaluate prosecution history, and identify additional relevant patents not listed in PAT-INFORMED through independent assignee and claim-based searches. The FTO analysis begins where PAT-INFORMED ends, not where it finishes.
Use Case 7: Tender Design for Hospital Formulary or Government Payer Programs
Rating: Partially adequate for non-U.S. markets, inadequate for the U.S. market. For a national health authority in a developing country designing a medicines tender, PAT-INFORMED provides preliminary patent status indication useful for anticipating whether competitive bidding is possible. For a U.S. hospital system or government payer managing formulary transitions, the settlement-based competitive entry dates are the operative planning variable, and PAT-INFORMED is silent on them.
Use Case 8: Regulatory Strategy and Patent Listing Decisions
Rating: Not applicable. PAT-INFORMED is a search tool for users of patent information, not a resource for companies managing their own patent listing obligations. Drug sponsors listing patents in the Orange Book follow FDA listing regulations under 21 C.F.R. § 314.53 and similar country-specific requirements. PAT-INFORMED has no role in that process.
How to Build a Global LOE Calendar: Integrating PAT-INFORMED with Other Primary Sources
A global LOE calendar — tracking loss-of-exclusivity dates for a pharmaceutical portfolio across multiple countries — is one of the most analytically demanding exercises in pharmaceutical competitive intelligence because the operative LOE date in each country reflects a different combination of local patent laws, SPC frameworks, data exclusivity rules, compulsory license histories, and voluntary license agreements. No single database provides this information; assembly requires systematic cross-referencing of multiple primary and secondary sources.
Building the Country-by-Country Patent Status Matrix
The starting point is identifying the relevant patent families for the target drug. For a global pharmaceutical company, a blockbuster drug may be covered by the same patent family filed through the PCT process across 40 to 60 countries, with additional national filings in key markets. The PCT application history is searchable through PATENTSCOPE; the national entry and grant status requires checking each relevant national patent office database.
PAT-INFORMED provides a compressed version of this country-by-country matrix for the participating companies’ products in the covered therapeutic areas — it lists patents by country, drawn from company disclosures. The compression is useful for speed but carries the completeness caveats already discussed. For a comprehensive global matrix, PATENTSCOPE and national office searches provide the independent verification layer.
Layering Regulatory Exclusivity onto the Patent Map
After establishing the patent status by country, regulatory exclusivity status must be added. This requires country-specific research for each major market: the Orange Book and FDA exclusivity database for the U.S.; SPC status at national IP offices for EU member states and the UK; equivalent mechanisms in Japan (the Pharmaceutical and Medical Device Act provides data exclusivity periods), Canada, Australia (the Australian Register of Therapeutic Goods has associated patent information), and other markets. Each jurisdiction has different exclusivity durations and different mechanisms for extending them.
MedsPaL provides regulatory exclusivity data for LMIC-focused analyses. For developed market regulatory exclusivities, no free consolidated resource exists — the analyst must check each market’s relevant regulatory authority individually.
Monitoring for LOE Date Changes: Why Static Analysis Is Wrong
LOE dates change. A Paragraph IV litigation verdict can move the effective generic entry date earlier than the patent expiry. A settlement can set a negotiated entry date that differs from both the litigation outcome and the patent expiry. A maintenance fee lapse can extinguish a patent years before its nominal expiry. A pediatric exclusivity grant can extend protection six months beyond what the patent record shows. A compulsory license issuance can open a market earlier than the patent or exclusivity expiry in a specific country.
Static LOE analysis — a one-time database search that produces a fixed date — is inadequate for any decision that depends on LOE accuracy over time. The correct operational model is continuous monitoring: tracking the Orange Book monthly for patent listing changes, the FDA Paragraph IV Certification List for new ANDA filings, the USPTO for maintenance fee payments and PTA/PTE adjustments, PACER for litigation developments, and company filings and press releases for settlement announcements. DrugPatentWatch’s monitoring and alerting functionality is designed for this continuous intelligence requirement. PAT-INFORMED has no alerting or monitoring capability — a user who searched the database six months ago has no mechanism for receiving updates on changes in the patent status of the medicines they queried.
The Patent Cliff 2025-2030 and What PAT-INFORMED Tells You About It
Between 2025 and 2030, the pharmaceutical industry faces what market analysts commonly describe as the second patent cliff — a wave of LOE events across blockbuster branded drugs larger in aggregate revenue exposure than the 2011-2012 cycle that saw the transition of Lipitor (atorvastatin), Plavix (clopidogrel), and Zyprexa (olanzapine) into the generic domain. The current wave encompasses both large-molecule biologics with complex secondary patent estates and significant small-molecule franchises with active Paragraph IV litigation landscapes.
Key Drugs Facing LOE 2025-2030: What the Patent Landscape Looks Like
Merck’s Keytruda (pembrolizumab) faces a compound patent expiry in the early 2028 timeframe, with biosimilar development programs already advanced at multiple manufacturers. Merck’s Januvia (sitagliptin) settlement-based generic entry has already begun in 2026. Bristol Myers Squibb’s Eliquis (apixaban) has faced Paragraph IV challenges, with settlement terms that will define its effective U.S. LOE timeline. Johnson and Johnson’s Stelara (ustekinumab) entered its biosimilar competition phase in 2023-2024 following BPCIA exclusivity expiry. AbbVie’s Skyrizi (risankizumab) and Rinvoq (upadacitinib) will face their own LOE timelines as the decade progresses.
PAT-INFORMED would show, for each of these drugs, the patents voluntarily disclosed by the originator companies in the therapeutic categories covered by the database. It would not show the BPCIA exclusivity calendar for the biologics, the Paragraph IV certification and settlement landscape for the small molecules, or the negotiated entry dates that define when competition actually begins rather than when patents theoretically expire. The $200-400 billion revenue-at-risk figure for the 2025-2030 period is an estimate with genuine uncertainty embedded in it — uncertainty about litigation outcomes, biosimilar entry timelines, IRA negotiation schedules, and private settlement terms. None of the uncertainty is reducible by consulting PAT-INFORMED.
The 80-90% Revenue Erosion After Generic Entry: Why Getting the LOE Date Right Has Quantifiable Value
For a small-molecule blockbuster entering multi-source generic competition, the brand’s unit share typically falls to 16% or less within the first year. The price erosion is equally severe — generic prices on day one of multi-source competition can run 80-85% below the brand price, with further compression as additional generic manufacturers enter. The revenue model for the brand effectively resets to a fraction of its pre-LOE base within 12 to 18 months of multi-source competition arriving.
A company, investor, or supply chain manager who places the LOE date six months later than the actual competitive entry date has modeled six months of brand-level revenue that will not materialize. For a drug generating $6 billion annually, six months of brand-level revenue is approximately $3 billion. The cost of the analytical error is not theoretical; it is the value of the planning decisions — launch preparation, inventory management, sales force repositioning, manufacturing scale-down — that could have been executed six months earlier. Getting the LOE date right, to the degree any database or analysis can achieve that precision, is worth the investment in tools that go beyond PAT-INFORMED’s capabilities.
Comparing PAT-INFORMED to Cortellis, Evaluate Pharma, and Other Commercial Intelligence Platforms
The commercial pharmaceutical intelligence market includes a range of platforms that incorporate patent data alongside clinical, regulatory, and financial data: Clarivate’s Cortellis, IQVIA’s various intelligence products, Evaluate Pharma, Informa Pharma Intelligence (formerly Citeline), and others. These platforms serve different primary audiences — Cortellis is oriented toward competitive intelligence in drug development; Evaluate Pharma toward investor-focused revenue and LOE modeling — and their patent data is one layer within a broader data architecture.
Where PAT-INFORMED’s Free Model Has an Advantage
PAT-INFORMED is free. Cortellis, Evaluate Pharma, and DrugPatentWatch all require subscriptions. For a procurement agency in a developing country with a limited budget for information tools, free versus paid is not a minor factor — it is the deciding factor. WIPO’s hosting of PAT-INFORMED under the UN system’s institutional imprimatur also provides a level of perceived credibility in government procurement contexts that a commercial database may lack, regardless of the comparative data quality.
For the specific use case of initial patent status orientation for LMIC procurement — the use case the database was designed for — free access is a genuine feature, not just a cost reduction. It means PAT-INFORMED is available to procurement agencies that would never access DrugPatentWatch or Evaluate Pharma, which expands the information-accessible population even if the information provided has the caveats described above.
Where Commercial Intelligence Platforms Outperform PAT-INFORMED Across Every Other Dimension
For any analytical use case beyond LMIC procurement orientation, commercial intelligence platforms provide data that PAT-INFORMED structurally cannot. DrugPatentWatch links patent data to ANDA filing histories, litigation outcomes, regulatory exclusivities, and settlement-based entry dates. Cortellis integrates patent data with clinical trial registrations and regulatory approval timelines. Evaluate Pharma models LOE-adjusted revenue trajectories based on patent expiry, biosimilar entry projections, and historical brand erosion patterns. None of these capabilities have a PAT-INFORMED equivalent.
The meaningful question for a professional deciding whether to use PAT-INFORMED is not “Is this better than Cortellis?” — it clearly is not, for developed-market applications — but “Is this better than the alternative sources available in my context?” For a national health ministry in a country with no equivalent domestic resource and no budget for commercial platforms, PAT-INFORMED is better than the alternative. For a generic company’s ANDA strategy team, a hospital system’s formulary committee, or an investment analyst’s portfolio modeling exercise, the relevant alternative is a multi-source primary research process augmented by commercial intelligence tools, and PAT-INFORMED is not in that conversation.
Practical Recommendations: When to Use PAT-INFORMED, When to Use MedsPaL, When to Use the Orange Book, and When to Use DrugPatentWatch
The decision tree for choosing a patent information tool should follow the structure of the question being asked, the geography of the market in focus, and the stakes of the decision that depends on the answer.
Use PAT-INFORMED When:
You need a free, fast, first-pass orientation on whether a specific medicine is under patent in a specific country, you are working in a LMIC context where the relevant market is not covered by a domestic Orange Book equivalent, and you have neither the budget for commercial intelligence tools nor immediate access to national patent office databases. Use it as a preliminary screen, not a final answer. Always note that absence of a patent listing does not mean no patents exist. Always cross-reference with MedsPaL for LMIC-focused analysis and with national patent office databases where available before making a procurement decision that depends on patent status.
Use MedsPaL When:
You are analyzing patent and licensing status for medicines in LMICs, particularly for HIV, hepatitis C, tuberculosis, and essential medicines categories. MedsPaL’s public-record-based sourcing is more reliable for identifying patent-free procurement opportunities, and its explicit coverage of voluntary licenses and compulsory licenses makes it the better tool for understanding actual procurement options rather than just patent listing status. Use MedsPaL as the primary source for LMIC analysis and PAT-INFORMED as a secondary check, not the other way around.
Use the FDA Orange Book When:
You are analyzing U.S. market LOE dates for small-molecule drugs. The Orange Book is the mandatory starting point for U.S. analysis. It provides Orange Book-listed patents with their expiry dates, and the regulatory exclusivity section provides NCE, Orphan, three-year, and pediatric exclusivity end dates. Supplement with the USPTO Patent Center for PTA/PTE adjustments, the FDA Paragraph IV Certification List for ANDA challenge activity, and PACER for litigation and settlement tracking. Use the Purple Book for biologics, noting that it shows BPCIA exclusivity dates but not the full patent landscape.
Use DrugPatentWatch When:
You need structured, aggregated intelligence on U.S. and global pharmaceutical patent and exclusivity status across large product portfolios, with integration of ANDA filing history, Paragraph IV litigation tracking, first-filer eligibility determinations, settlement monitoring, and automated alerting for changes. DrugPatentWatch draws from the same primary sources — the Orange Book, the USPTO, the FDA Paragraph IV Certification List — and supplements them with historical filing data and litigation tracking to provide the integrated view that formulary management, generic development strategy, supply chain planning, and investment analysis require. For analysts who need to track dozens or hundreds of drugs simultaneously and cannot manually check four primary sources per drug per month, it is the operationally necessary tool.
Key Takeaways
PAT-INFORMED is a free, INN-searchable global patent database built on voluntary, unverified disclosures from 20 originator pharmaceutical companies. Its data reflects what those companies chose to report, not an independent determination of patent status.
The database’s self-reporting model creates a predictable bias: it may overstate patent coverage in markets where the patent holder benefits from deterring generic procurement, and it systematically omits information about patent withdrawals, expired patents in specific jurisdictions, and voluntary licenses that permit generic supply.
MSF’s 2019 technical brief to WIPO’s Standing Committee on Patents documented specific examples of incomplete and potentially misleading data, including the daclatasvir case where BMS’s patent withdrawals in multiple LMIC markets were absent from the database.
PAT-INFORMED covers small-molecule drugs only, in six therapeutic areas, for products of 20 participating companies. It does not cover biologics, devices, or manufacturers outside the IFPMA network.
For U.S. LOE analysis, PAT-INFORMED provides no information on FDA regulatory exclusivities, Patent Term Adjustments, Patent Term Extensions, pediatric exclusivity, Paragraph IV certification history, litigation status, or settlement-based entry dates. All five of those inputs are required for accurate U.S. LOE determination.
For LMIC procurement analysis, PAT-INFORMED should be used alongside MedsPaL, not as a substitute for it. MedsPaL’s public-record-based sourcing and explicit licensing information make it more reliable for identifying genuine procurement opportunities.
An accurate drug LOE date in the U.S. market requires: the Orange Book patent listing, USPTO verification of PTA and PTE adjustments, FDA exclusivity database review, FDA Paragraph IV Certification List review, and PACER monitoring for active litigation and settlement agreements.
DrugPatentWatch aggregates these five inputs and tracks global patent landscapes across 134 countries, enabling both the initial landscape mapping and the ongoing monitoring that formulary management, generic development planning, and investment analysis require.
The 30% procurement cycle reduction attributed to PAT-INFORMED refers to the initial research phase only. It does not reduce the need for independent legal verification in high-stakes procurement decisions.
Supplementary Protection Certificates in the EU, data exclusivity protections globally, and Orphan Drug Exclusivities in the U.S. all extend effective market protection beyond patent expiration dates and are absent from PAT-INFORMED’s coverage architecture.
Frequently Asked Questions
Is PAT-INFORMED reliable for finding drug patent expiry dates?
Partially. The database provides patent information self-reported by 20 originator pharmaceutical companies, which means the data reflects the patent holder’s disclosure choices rather than an independent determination. For an initial orientation on whether a medicine is under patent in a specific country, it is useful. For a definitive LOE date used in procurement or investment decisions, independent verification against primary sources is required.
What is the difference between PAT-INFORMED and the FDA Orange Book?
The Orange Book covers U.S.-approved drug products and links them to both Orange Book-listed patents and FDA-granted regulatory exclusivities. Drug sponsors have a legal obligation to list qualifying patents, subject to false-listing penalties. PAT-INFORMED covers medicines globally across six therapeutic areas, using voluntary disclosures from participating companies, with no regulatory obligation to be complete or accurate, and no coverage of regulatory exclusivities. For U.S. LOE analysis, the Orange Book is the mandatory starting point; PAT-INFORMED adds nothing to it.
Can I use PAT-INFORMED to determine if a generic drug can be legally sold in my country?
Not definitively. PAT-INFORMED can tell you which patents a company has disclosed for a medicine in your country, but it does not show withdrawn patents, expired patents, patents that were never filed, or voluntary licenses that may permit generic supply even while a patent remains in force. Use PAT-INFORMED as a preliminary screen and cross-reference with MedsPaL and your national patent office database before making a procurement determination.
Does PAT-INFORMED cover biologic drugs and biosimilars?
No. PAT-INFORMED covers small-molecule drugs only. Biologic drugs, including monoclonal antibodies, fusion proteins, and other large-molecule therapeutics, are not covered. Biosimilar LOE analysis requires a different framework centered on BPCIA exclusivity periods, the Purple Book, and the litigation/settlement landscape for each reference product.
How accurate is PAT-INFORMED for oncology drugs?
Accuracy varies considerably. For oncology drugs developed by participating companies, PAT-INFORMED provides the patents those companies chose to disclose, subject to the completeness caveats above. For oncology drugs developed by non-participating companies, including many targeted therapies, cell and gene therapies, and ADCs, the database has no coverage. Oncology is the therapeutic area with the highest branded revenue concentration and the most complex patent landscapes; PAT-INFORMED covers only a fraction of it.
What is MedsPaL and when should I use it instead of PAT-INFORMED?
MedsPaL, operated by the Medicines Patent Pool, is a patent and licensing database that draws its data from national patent offices and public licensing agreements rather than patent-holder voluntary disclosures. For LMIC procurement analysis, MedsPaL is generally more reliable for identifying patent-free procurement opportunities because it sources from independent public records and includes licensing information that PAT-INFORMED excludes. Use both tools in combination and treat discrepancies as flags requiring independent verification.
Why don’t patent expiry dates in PAT-INFORMED match dates I see elsewhere?
Several reasons: patent databases track different patent types (some track API patents, others include formulation and device patents); Patent Term Adjustments and Patent Term Extensions modify expiry dates beyond the 20-year statutory term; regulatory exclusivities extend competition barriers beyond patent expiry; and settlement agreements create effective LOE dates that differ from both patent expiry and exclusivity end dates. No single database captures all these variables simultaneously, which is why a multi-source approach is required for precise LOE analysis.
Does PAT-INFORMED track Paragraph IV patent challenges?
No. PAT-INFORMED has no awareness of the ANDA process or Paragraph IV certification filings. For U.S. generic entry analysis, tracking Paragraph IV certifications — which can signal patent challenges that result in generic entry years before patent expiry — requires the FDA Paragraph IV Certification List and PACER litigation monitoring, neither of which PAT-INFORMED integrates.
How does Patent Term Extension (PTE) affect drug LOE dates, and does PAT-INFORMED reflect it?
PTE under 35 U.S.C. § 156 compensates patent holders for regulatory review time, adding up to five years to the patent term of one designated patent per drug product, with a ceiling of 14 years of effective protection after FDA approval. For many drugs, PTE extends the operative compound patent by two to four years beyond its nominal expiry. PAT-INFORMED does not consistently reflect PTE grants; verifying PTE status requires a direct search of the USPTO Patent Term Extension database for each product.
What role do Supplementary Protection Certificates play in European drug LOE analysis, and does PAT-INFORMED cover them?
SPCs are EU and UK regulatory instruments that extend effective patent-based market protection for up to five years beyond the basic patent expiry, with an additional six-month pediatric extension available. They are granted by national IP offices and vary across EU member states. SPCs are not patents and are not reflected in PATENTSCOPE or PAT-INFORMED. For European LOE analysis, SPC status must be checked separately at each relevant national IP office, making country-by-country European LOE analysis significantly more complex than a U.S. analysis centered on the Orange Book.
Citations
World Intellectual Property Organization. (n.d.). PAT-INFORMED – The Gateway to Medicine Patent Information. WIPO. https://www.wipo.int/pat-informed/en/
International Federation of Pharmaceutical Manufacturers and Associations. (2023). Pat-INFORMED backgrounder. IFPMA. https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Pat-INFORMED-backgrounder-FINAL.pdf
Médecins Sans Frontières Access Campaign. (2020, February 26). Technical briefing: Public health concerns on PAT-INFORMED database. Prepared for the WIPO Standing Committee on Patents. https://msfaccess.org/sites/default/files/2020-03/WIPO%20SCP-TechnicalBriefing-FINAL-26Feb2020_ENG.pdf
Medicines Patent Pool. (n.d.). MedsPaL: Medicines Patents and Licences Database. MPP. https://medicinespatentpool.org/what-we-do/medspal
Medicines Patent Pool. (2024, May 7). The Medicines Patent Pool unveils new version of MedsPaL for streamlined access to global health intellectual property information. MPP. https://medicinespatentpool.org/news-publications-post/the-medicines-patent-pool-unveils-new-version-of-medspal-for-streamlined-access-to-global-health-intellectual-property-information
World Intellectual Property Organization. (n.d.). PAT-INFORMED FAQs. WIPO. https://www.wipo.int/pat-informed/en/faqs/
DrugPatentWatch. (2026, March 22). Drug patent expiration: The complete strategic guide to loss of exclusivity, lifecycle management, and the $400 billion cliff. https://www.drugpatentwatch.com/blog/the-impact-of-drug-patent-expiration-financial-implications-lifecycle-strategies-and-market-transformations/
DrugPatentWatch. (2025, December 16). The patent cliff playbook: A strategic guide to tracking and capitalizing on pharmaceutical loss of exclusivity. https://www.drugpatentwatch.com/blog/the-patent-cliff-playbook-a-strategic-guide-to-tracking-and-capitalizing-on-pharmaceutical-loss-of-exclusivity/
DrugPatentWatch. (2026, March 3). “We missed the LOE date”: How pharma vendors lose millions by tracking expiry wrong. https://www.drugpatentwatch.com/blog/we-missed-the-loe-date-how-pharma-vendors-lose-millions-by-tracking-expiry-wrong/
DrugPatentWatch. (2026, February 23). Know before the cliff: How to forecast drug patent expiry. https://www.drugpatentwatch.com/blog/know-before-the-cliff-how-to-forecast-drug-patent-expiry/
DrugPatentWatch. (2026, February 28). Win the patent cliff: How to track patent expiry and exclusivity windows using the FDA Orange Book. https://www.drugpatentwatch.com/blog/win-the-patent-cliff-how-to-track-patent-expiry-and-exclusivity-windows-using-the-fda-orange-book/
DrugPatentWatch. (2026, March 3). Patent vs. regulatory exclusivity: The critical difference in forecasting a drug’s market longevity. https://www.drugpatentwatch.com/blog/patent-vs-regulatory-exclusivity-the-critical-difference-in-forecasting-a-drugs-market-longevity/
DrugPatentWatch. (2026, March 8). Read the Orange Book, then ignore it: How smart supply chains use patent intelligence. https://www.drugpatentwatch.com/blog/read-the-orange-book-then-ignore-it-how-smart-supply-chains-use-patent-intelligence/
DrugPatentWatch. (2026, March 19). Pharmaceutical patent term extensions and supplementary protection certificates: The complete technical reference. https://www.drugpatentwatch.com/blog/understanding-patent-term-extensions-an-overview/
DrugPatentWatch. (2026, March 10). Two clocks, one drug: How patents and FDA exclusivity actually determine when your drug faces competition. https://www.drugpatentwatch.com/blog/two-clocks-one-drug-how-patents-and-fda-exclusivity-actually-determine-when-your-drug-faces-competition/
DrugPatentWatch. (2026, December 14). The iceberg illusion: Why tracking drug expiry dates is the least important part of patent risk. https://www.drugpatentwatch.com/blog/the-iceberg-illusion-why-tracking-drug-expiry-dates-is-the-least-important-part-of-patent-risk/
Graham, S. J. H., Haber, G., & Tunnell, J. C. (2024). The NBER Orange Book Dataset: A user’s guide. PMC10731339. https://pmc.ncbi.nlm.nih.gov/articles/PMC10731339/
Hoekman, J., Bos, J., Boersma, C., & Postma, M. J. (2022). Estimating potential for drug budget reallocation following expiration of exclusivity of pharmaceutical products. PMC8813194. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813194/
Beall, R. F., Darrow, J. J., & Kesselheim, A. S. (2016). Is patent “evergreening” restricting access to medicine/device combination products? PLOS ONE, 11(2), e0148939. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766186/
U.S. Food and Drug Administration. (2015). Patents and exclusivity. FDA. https://www.fda.gov/media/92548/download
U.S. Food and Drug Administration. (n.d.). Patent certifications and suitability petitions. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions
Pharmaceutical Technology. (2018, December 6). Pat-INFORMED: The solution to drug patent procurement issues? https://www.pharmaceutical-technology.com/features/pat-informed-drug-patent-procurement-issues/
Medicines Law & Policy. (2018, September). WIPO and pharma industry launch global medicines patent database. https://medicineslawandpolicy.org/2018/09/wipo-and-pharma-industry-launch-global-medicines-patent-database/
Alacrita. (n.d.). Pharmaceutical patent term extension: An overview. https://www.alacrita.com/whitepapers/pharmaceutical-patent-term-extension-an-overview
